Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...
Fourth-quarter highlightsOrders of $7.5 billion, including $3.8 billion of IET orders.RPO of $33.1 billion, including IET RPO of $30.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback